Epstein-Barr Virus-Associated Carcinoma of the Larynx: A Systematic Review with Meta-Analysis

Marcos Antonio Pereira de Lima 1,2,*, Áliffe Diogo Lima Silva 1, Antônio Carlos Silva do Nascimento Filho 1, Thiago Lima Cordeiro 1, João Pedro de Souza Bezerra 1, Maria Aline Barroso Rocha 1, Sally de França Lacerda Pinheiro 1, Roberto Flávio Fontenelle Pinheiro Junior 1, Maria do Socorro Vieira Gadelha 1 and Cláudio Gleidiston Lima da Silva 1

Abstract: Over the past few decades, several publications have investigated the role of Epstein-Barr virus (EBV) in head and neck squamous cell carcinomas, and an increasing number of them have shown its presence in laryngeal tumors. The purpose of this meta-analysis was to evaluate the association of EBV with laryngeal carcinoma. The search was carried out in two databases, Scopus and PubMed, using the following terms: “Epstein-Barr virus” and “laryngeal carcinoma”. A total of 187 records were found, of which 31 were selected for meeting the inclusion and exclusion criteria. The meta-analysis yielded an overall pooled prevalence of 43.72% (95% confidence interval (CI): 34.35–53.08). Studies carried out in Europe and Eurasia had slightly higher pooled prevalence than other subgroups, while the prevalence of studies performed in developed countries was higher than in developing countries (46.37% vs. 34.02%). Furthermore, laryngeal carcinoma occurred almost three times as often among EBV-infected individuals compared to those without EBV infection (odds ratio = 2.86 (95% CI: 1.18–6.90); Begg’s test, p = 0.843 and Egger’s test, p = 0.866). Our findings support the idea that EBV is related to laryngeal carcinoma. However, further studies are needed before recognizing a definitive etiological role of EBV in the development and/or progression of laryngeal carcinomas.

Keywords: Epstein-Barr virus (EBV); laryngeal carcinoma; carcinogenesis; oncovirus

1. Introduction

According to the global estimates from the International Agency for Research on Cancer (IARC), for 2018, there were 177,422 new cases and 94,771 deaths due to cancers of the larynx. Both values (incidence and mortality) represented about 1.0% of all 36 cancers analyzed [1]. Histologically, squamous cell carcinoma (SCC) is the most frequent type with 90–95% of the laryngeal cancer cases [2,3]. In turn, laryngeal carcinoma (LC) accounts for 25% to 40% of head and neck malignancies [4].

Although it is well known that tobacco smoking and alcohol consumption are the major risk factors for the development of laryngeal SCC, infectious agents may also be implicated in the pathophysiology of some cases [2,4]. In this scenario, Epstein-Barr virus (EBV) arises as a potential candidate considering all the evidence gathered so far on its oncogenic role in several lymphoid and epithelial malignancies, including head and neck squamous cell carcinomas (HNSCC) [5]. EBV is etiologically linked to undifferentiated nasopharyngeal carcinoma (NPC) [6], and a recent meta-analysis has shown that EBV-infected individuals have a 2.5 times higher risk for developing oral carcinoma [7].
Additionally, various genotypes of human papillomavirus (HPV) have been found in samples of laryngeal SCC [4]. Thus, the laryngeal epithelium seems to share similarities with oral and anogenital epithelia, in which parts of the carcinomas have shown the involvement of the aforementioned viruses [8]. It is worth mentioning that oncoviruses contribute to approximately 12–15% of human cancers worldwide, while EBV and HPV are reportedly involved in 38% of all virus-related cancers [9].

Bricháček et al. [10] were the first to successfully demonstrate the presence of the EBV genome and the latent protein EBNA (Epstein-Barr virus nuclear antigen) in malignant cells of laryngeal carcinomas. The presence of viral DNA in most of the tumor cells suggested that EBV might be associated with LC, resembling EBV-infected NPC. Subsequently, the EBV receptor molecule (CD21) was identified on the surface of primary cultured laryngeal carcinoma epithelial cells [11]. Since then, a few studies have been conducted, applying different techniques such as polymerase chain reaction (PCR), in situ hybridization (ISH), and immunohistochemistry (IHC), and exploring molecular and histological approaches [12–20]. Even so, the role of EBV in laryngeal carcinomas is still not fully elucidated. To the best of our knowledge, there is no systematic review, with or without meta-analysis, on this subject in the literature.

In the present study, we performed a systematic review with meta-analysis of articles available in the international literature on the association of EBV with carcinomas of the larynx, in order to answer the following research question: Are EBV-infected individuals at increased risk for the development and/or progression of laryngeal carcinoma? Characteristics of the studies, such as reported prevalence, techniques used, detection targets, and other relevant aspects for understanding of the relationship between EBV and laryngeal carcinomas, were evaluated.

2. Results

2.1. Characteristics of the Studies

The 31 systematically reviewed studies were carried out in 19 different countries in Europe (n = 12) [6,10–20], Asia (n = 8) [21–28], North America (n = 5) [3,29–32], Eurasia (n = 3) [4,5,33], Oceania (n = 1) [34], South America (n = 1) [2], and concomitantly in North America and Europe (n = 1) [35] (Table 1).

The studies have detected EBV by PCR-based techniques (n = 16) [3–5,12,13,15,17,18,21,23,25,28,31–34], in situ hybridization (ISH) (n = 14) [2,10,12,14,16,19,20,22,26–28,31,32,35], or immunological methods (n = 10) [5,10,12,14,16,24,28–30,35]. In seven studies, two techniques were used for viral detection, with five studies combining immunological assays and hybridization [4,10,14,16,35]: a study using immunological and PCR-based techniques [5] and another study applying ISH and PCR-based techniques [32]. Three different techniques (ISH, immunological, and PCR-based methods) were employed in two studies [12,28].

Some articles also explored the presence of other viruses. In order to investigate the possible association between viral (co)infection and a laryngeal carcinogenesis, these data were also considered in the present systematic review and summarized in Table 1. HPV has been investigated in 12 studies [2,12,15,16,18–20,23,25,26,34,35]. A few studies assessed other human herpesvirus (HHV) members, namely, human herpesvirus type 1 (HHV-1, also known as herpes simplex virus type 1, HSV-1) was investigated in three studies [17,29,35]; HHV-2 (or HSV-2) in three studies [10,29,35]; cytomegalovirus (CMV or HHV-5) in one study [17]; and HHV-8 (also known as Kaposi’s sarcoma herpesvirus—KSHV) in two studies [16,35]. The presence of human immunodeficiency virus (HIV) was explored in two studies [16,35]. Some human polyomaviruses were also analyzed in four studies, including Merkel cell polyomavirus (MCV or MCPyV) in two studies [3,20]; BK virus (BKV) in one [18]; and the viral load of John Cunningham virus (JCV) in another one [25].
Table 1. Summary of the 31 studies that evaluated EBV in laryngeal carcinomas.

| Country          | Specimen | Age Range                  | EBV (Carcinoma) | EBV (Control Group) | HPV | Co-Infection | Other Viruses | Authors       | Year |
|------------------|----------|----------------------------|-----------------|---------------------|-----|--------------|---------------|---------------|------|
| USA              | Serum    | N.A.                       | Complement fixation test | Anti-EBV 27/39 (69.2%) | Serum | Complement fixation test | Anti-EBV 38/59 (64.4%) | -            | -    |
| Czech Republic   | Fresh frozen | From 46 to 69 years old | ISH EBV DNA 3/5 (60%) | -               | -    | -            | -             | HHV-1/40 (100%) | Sessions et al. [29] | 1974 |
| USA              | Serum    | N.P.                       | Serological assay Anti-EBNA GMT = 54.8 | Healthy control | Anti-EBNA GMT = 13.8 | -    | -            | Callaghan et al. [30] | 1983 |

Techniques: Anti-EBN, Anti-EBNA, Anti-EA, Anti-VAC, Mean antibody titers/5 (22%), Mean antibody titers/5 (32%), Mean antibody titers/5 (42%).
Table 1. Cont.

| Country     | Specimen         | Age Range | EBV (Carcinoma) | EBV (Control Group) | HPV | Co-Infection | Other Viruses | Authors          | Year |
|-------------|------------------|-----------|-----------------|---------------------|-----|--------------|---------------|-----------------|------|
| Taiwan      | Throat washings  | N.A.      | Nested-PCR      | BNLF1 (LMP1)        | 20/31 (64.5%) | -             | -             | Jeng et al. [21]. | 1994 |
|             |                  |           |                 |                     |     |              |               |                 |      |
|             |                  |           |                 |                     |     |              |               |                 |      |
| Sweden      | FFPET            | N.A.      | Nested-PCR      | EBNA-1              | 1/6 (16.6%)  | Laryngeal papilloma | Nested-PCR | Lewensohn-Fuchs et al. [12] | 1994 |
|             |                  |           |                 |                     |     |              |               |                 |      |
|             |                  |           |                 |                     |     |              |               | Kiaris et al. [13] | 1995 |
| USA         | FFPET            | From 51 to 82 years old Mean: 64 | ISH EBER-1 | 0/4 (0%) | - | - | - | - | - | MacMillan et al. [31] | 1996 |
| Switzerland | FFPET            | From 53 to 73 years old Mean: 65.75 | ISH EBER | 3/4 (75%) | - | - | - | - | - | Zbären et al. [14] | 1997 |
| South Korea | FFPET-tissue microarray | N.P. | ISH EBERs | 0/93 (0%) | - | - | - | - | - | Yang et al. [22] | 2001 |
| Country         | Specimen | Age Range | EBV              | EBV (Carcinoma) | HPV | Co-Infection | Other Viruses | Authors        | Year |
|----------------|----------|-----------|------------------|----------------|-----|--------------|---------------|----------------|------|
| Turkey         | FFPET    | Mean: 52  | PCR gp350        | Vocal cord nodules (Mean 38 years) | PCR gp350 | 7/17 (41.17%) | -             | -              | 2003 |
| USA            | Fresh Frozen | N.A. | qPCR EBNA1 and BamHI-W | 18/84 (21.42%) | - | - | - | - | Goldenberg et al. [32] 2004 |
| China          | FFPET    | From 38 to 75 years old | PCR LMP1 | 12/132 (9.13%) | PCR and E6 region | 68/132 (52.03%) | HPV16 | - | Liu et al. [23] 2005 |
| Greece         | Fresh frozen | From 40 to 77 years old | PCR EBV | 39/90 (43.3%) | PCR HPV and 16 and 18 DNA | 36/90 (40%) | HPV16 and HPV 18 | - | Vlachsis et al. [15] 2005 |
| Brazil         | FFPET    | From 25 to 86 years old | ISH EBER1 | 0/110 (0%) | Multiplex PCR and L1 gene | 41/110 (37.3%) | HPV16 and HPV 18 | - | De Oliveira et al. [2] 2006 |
| Australia      | FFPET    | From 12 to 15 years old | PCR-Southern blot BamHI-W | 0/3 (0%) | PCR-ELISA and L1 gene | 2/3 (66.6%) | HPV16 | - | Chow et al. [34] 2007 |
| Iraq and Jordan | Serum | Median: 50.5 Mean: 50.81 | ELISA IgA anti-VCA | Serum (patient free of cancer or any other medical illness) | ELISA IgA anti-VCA | Mean ELISA OD EBV serum/100 (0.094 ± 0.007) | - | - | Abdulamir et al. [24] 2008 |
| Country   | Specimen  | Age Range          | EBV (Carcinoma) | EBV (Control Group) | HPV | Co-Infection | Other Viruses | Authors       | Year |
|----------|-----------|--------------------|-----------------|---------------------|-----|--------------|---------------|---------------|------|
| Spain    | FFPET     | From 36 to 54 years old |     |                     |     |              |               |               |      |
|          |           | Mean: 42.6 Median: 41.5 |     |                     |     |              |               | Moyano et al. [16] | 2009 |
|          |           | ISH                 | EBER1 and 2     | 0/6 (0%)            |     |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
| Turkey   | Fresh frozen | Mean: 54.6 | qPCR         | EBV DNA             | 10/20 (50%) |     |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               | Rota et al. [5] | 2010 |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
| Japan    | FFPET     | From 27 to 91 years old |     |                     |     |              |               | Zheng et al. [25] | 2010 |
|          |           | Mean: 65.5 | qPCR         | LMP1                 | 49/65 (75.3%) |     |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
| USA and Spain | FFPET-tissue microarray | From 33 to 61 years old |     |                     |     |              |               | McLemore et al. [35] | 2010 |
|          |           | Mean: 47/36 Median: 46.5 |     |                     |     |              |               |               |      |
|          |           | ISH                 | EBER           | 2/11 (18.2%)        |     |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
| South Korea | FFPET-tissue microarray | N.A. |     |                     |     |              |               | Choe et al. [26] | 2012 |
|          |           | ISH                 | EBER           | 0/29 (0%)           |     |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
|          |           |                     |                 | -                   | -   |              |               |               |      |
| Country | Specimen | Age Range                | EBV | EBV (Carcinoma) | HPV | Co-Infection | Other Viruses | Authors           | Year  |
|---------|----------|--------------------------|-----|----------------|-----|--------------|---------------|------------------|-------|
| Turkey  | FFPET    | From 42 to 67 years old  | EBV DNA | 10/25 (40%) | EBV DNA | 8/17 (47.1%) | -             | Muderris et al. [4] | 2013  |
|         |          | Mean: 54.6               | Benign laryngeal lesion (mean: 48.8 years)         |Real-time-qPCR| real-time-qPCR| PCR L1 region| -             |                  |       |
| Poland  | Fresh    | Nested-PCR               | DNA pol B | 30/50 (60%) | PCR L1 gene | 18/50 (36%) | CMV (4/50 (8%), HHV-1 (6/50, 12%) | Polz-Gruszka et al. [17] | 2015  |
|         | frozen   |                          | EBNA2   | 12/40 (30%)  | -            | 6/40 (15%)   | 28 types of HPV (especially HPV type 16) | Drop et al. [18] | 2017  |
| Poland  | Fresh    | Nested-PCR               | EBNA2   | 12/30 (40%)  | -            | -            | -             |                  |       |
|         | frozen   |                          |         |              |              |              |               |                  |       |
| Iraq    | FFPET    | From 25 to 78 years old | ISH   | EBER          | 12/30 (40%)  | ISH          | EBER          | Ali et al. [27] | 2018  |
|         |          | Mean: 53.6 ± 2.11        |       |              |              | 0/15 (0%)    |              |                  |       |
|         |          | Healthy control          |       |              |              |              |               |                  |       |
|         |          | (from 23 to 68 years-old; mean: 46.5 ± 2.81) |       |              |              |              |               |                  |       |
|         |          | Nodules                  | ISH   | EBER          | 2/13 (15.4%) | -            | -             |                  |       |
|         |          | (from 26 to 74 years old; mean: 44.2 ± 2.14) |       |              |              |              |               |                  |       |
|         |          | Polyps                   | ISH   | EBER          | 1/12 (8.3%)  | -            | -             |                  |       |
|         |          | (from 13 to 71 years old; Mean: 45.7 ± 3.39) |       |              |              |              |               |                  |       |
| Mexico  | FFPET    | From 40 to 89 years-old | qPCR  | LMP2          | 54/195 (27.7%) | PCR L1 region | HPV (especially HPV type 11) | Vazquez-Guillen et al. [3] | 2018  |
|         |          | Mean: 64.5               |       |              |              |              | 25/54 (46.3%) |                  |       |
| Country     | Specimen | Age Range          | EBV (Carcinoma) | EBV (Control Group) | HPV | Co-Infection | Other Viruses | Authors          | Year |
|-------------|----------|--------------------|-----------------|---------------------|-----|--------------|---------------|-----------------|------|
| Spain       | FFPET    | From 46 to 80 years-old Mean: 64 | ISH EBER 0/7 (0%) | - - - - | PCR and L1 gene | 63/195 (34.4%) | HR-HPV (especially HPV type 52) | Acuña et al. [19] | 2019 |
| Poland      | Serum    | From 40 to 79 years old | Immunoenzymatic assay | IgG anti-VCA 33/33 (100%) | Healthy patient serum | Immunoenzymatic assay | IgG anti-VCA 20/20 (100%) | - - - - - | Klatka et al. [6] | 2019 |
| Taiwan      | FFPET    | From 58 to 74 years-old Mean: 64 | qPCR BamHI W 22/42 (52%) | Non-malignant lesion (from 37 to 58 years old; mean: 52) | qPCR BamHI W 8/39 (20%) | - - - - - | - | Lee et al. [20] | 2021 |
| Netherlands | FFPET-tissue microarray | ISH EBER 28/42 (67%) | Non-malignant lesion | ISH EBER 22/39 (56%) | qPCR HR-HPV 0/9 (0%) | - | - | Mulder et al. [20] | 2021 |
|             | Serum    | qPCR BamHI W 2/30 (6.7%) | - - - - - | - - - - - | - | - | - | - | - |
|             | Serum    | Immunofluorescence IgG anti-VCA 4/30 (13%) | - - - - - | - - - - - | - | - | - | - | - |
|             | N.P.     | ISH EBER 0/9 (0%) | - - - - - | qPCR HR-HPV 0/9 (0%) | - | - | - | - | - |
| Country | Specimen | Age Range | EBV | EBV | HPV | Co-Infection | Other Viruses | Authors | Year |
|---------|----------|-----------|-----|-----|-----|-------------|---------------|---------|------|
| UK      | Primary cultures of a laryngeal carcinoma | Identification of a 200 kDa protein on the surface of primary cultures of a LC sharing an epitope with the C3d/EBV receptor molecule CD21 of B lymphocytes | | | | | Young et al. [11] | 1989 |

N.A., not available; N.P., data extraction not possible, because the authors did not present the age range information of the LC group separately from the other tumors.
2.2. Meta-Analysis

Collectively, the studies included in the present review gathered 1292 distinct specimens from patients with laryngeal carcinoma. Twenty-nine studies could be submitted to meta-analysis, of which eight studies presented a prevalence of 0 or 100% and were automatically excluded from the analysis. The overall pooled prevalence was 43.72% (95% CI: 34.35–53.08; \( p < 0.001 \)). Figure 1 shows the forest plot, applying the random-effects model due to the observed heterogeneity, with the prevalence of EBV and respective 95% CI for each study presented by subgroups established based on the type of technique used (immunological, in situ hybridization, or PCR-based method). The highest pooled prevalence was observed in the subgroup that used immunological techniques for EBV detection in LC: 50.68% (95% CI: 28.58–72.80; \( p < 0.001 \)). Subgroups that used the in situ hybridization and PCR-based technique yielded the following pooled prevalence: 49.58% (95% CI: 28.47–70.68; \( p = 0.004 \)) and 39.31% (95% CI: 27.84–50.77; \( p < 0.001 \)), respectively.

| Article                          | Sample          | Technique                          | Target            | %  |
|---------------------------------|-----------------|------------------------------------|-------------------|----|
| Overall (\( I^2 = 92.2\% \); \( p = 0.000 \)) |                 |                                    |                   |    |
| Muderris et al., 2017           | Serum           | qPCR-based                          | EBV DNA           | 40.00 (37.08, 43.94) |
| Lee et al., 2021                | Fresh frozen    | ISH                                | EBV DNA           | 39.31 (27.84, 50.77) |
| Zbären et al., 1997             | Serum           | Hybridization                       | EBV DNA           | 36.15 (27.94, 45.70) |
| Zbären et al., 1997             | Serum           | PCR                                | EBV DNA           | 42.72 (34.35, 53.08) |
| Subtotal (\( I^2 = 93.5\% \); \( p = 0.000 \)) |                 |                                    |                   |    |
| Subtotal (\( I^2 = 74.2\% \); \( p = 0.004 \)) |                 |                                    |                   |    |
| Subtotal (\( I^2 = 57.2\% \); \( p = 0.000 \)) |                 |                                    |                   |    |

Table 2 displays the results of the meta-analysis of the studies using the random-effects model, stratified by sampling method, world region, and degree of development of the country where the samples were collected. The pooled prevalence was similar in the following subgroups: serum; fresh frozen tissue; and formalin fixed, paraffin embedded tissues (FFPET). The highest pooled prevalence was observed in a subgroup consisting of a single study that used throat washings as samples; for this reason, no \( p \)-value was presented by the software (64.51%; 95% CI: 47.67–81.35).

Studies carried out in Europe and Eurasia had slightly higher pooled prevalence than other subgroups, whereas the prevalence of studies performed in developed countries (46.37%; 95% CI: 35.27–57.47; \( p < 0.001 \)) was higher than in developing countries.

In our sample, 15 case-control studies were identified and used in the odds ratio analysis [4–6,12,13,21,22,24,25,27–30,33,35]. Based on the results of the heterogeneity tests, the random-effects model was used to determine the odds ratio (Figure 2). The analysis between the LC versus normal control group revealed that EBV-infected individuals are almost three times more likely to develop laryngeal carcinoma (OR = 2.86 (95% CI: 2.32–3.52)).
1.18–6.90; \( p = 0.002 \)); in comparison, for the control group composed of non-malignant lesions, the chance of developing LC in EBV-positive individuals was nearly twice as common as in the non-infected group (OR = 1.94 (1.18–3.21); \( p = 0.299 \)). The results of the \( p \)-value and I-squared statistics in the latter analysis revealed low heterogeneity (\( I^2 < 50\% \) and \( p > 0.05 \)), therefore indicating the fixed-effects model as the most suitable, and both models had similar odds ratio results (OR = 2.00; 95% CI: 1.30–3.06; fixed-effects model). The overall result showed values closely related to those of the second subgroup (OR = 2.18 (95% CI: 1.33–3.59); \( p = 0.007 \)). Figure 3 presents a funnel plot along with results of two statistical tests to assess the risk of publication bias: Begg’s test (\( p = 0.843 \)) and Egger’s test (\( p = 0.866 \)). No evidence of publication bias was observed.

### Table 2. Results of meta-analysis with random-effects model in carcinoma cases: pooled prevalence of EBV detection and CI at 95% in subgroups analyzed.

| Analysis/Subgroup | N * | Pooled Prevalence | 95% CI | Heterogeneity Test |
|-------------------|-----|-------------------|--------|-------------------|
| Sample            |     |                   |        |                   |
| Serum             | 7   | 41.66             | 18.19–64.12 | 104.99 <0.001 94.3% |
| Fresh frozen tissue | 8  | 42.30             | 30.18–54.43 | 31.22 <0.001 77.6% |
| Throat washings   | 12  | 43.31             | 27.53–59.10 | 189.42 <0.001 94.2% |
| World region      |     |                   |        |                   |
| Asia              | 9   | 42.37             | 21.93–62.82 | 220.81 <0.001 96.4% |
| Eurasia           | 3   | 46.17             | 34.29–58.05 | 0.64 0.725 0.0% |
| Europe            | 10  | 48.17             | 36.87–59.47 | 30.75 <0.001 70.7% |
| North America (NA) | 5  | 40.42             | 22.23–58.60 | 43.26 <0.001 90.8% |
| NA and Europe     | 1   | 18.18             | –4.61–40.97 | 0.00 – – |
| Development status|     |                   |        |                   |
| Developed countries | 22 | 46.37             | 35.27–57.47 | 223.87 <0.001 90.6% |
| Developing countries | 6  | 34.02             | 19.88–48.17 | 49.05 <0.001 89.8% |
| Overall           | 28  | 43.72             | 34.35–53.08 | 347.80 <0.001 92.2% |

* N, number of members in each subgroup.

### Table 3. Results of meta-analysis with random-effects model in carcinoma cases: OR (95% CI) for EBV detection and CI at 95% in subgroups analyzed.

| Article                          | Technique          | OR (95% CI) | % Weight |
|----------------------------------|--------------------|-------------|----------|
| Normal control                   |                    | 1.55 (1.15, 1.98) | 8.72     |
| Severson et al., 1974            | Complement fixation test | 1.24 (0.93, 1.65) | 7.36     |
| Callaghan et al., 1983           | Serological assay  | 3.20 (1.63, 6.35) | 2.38     |
| Callaghan et al., 1983           | Complement fixation test | 2.12 (1.33, 3.59) | 2.38     |
| Callaghan et al., 1983           | Serological assay  | 3.04 (0.22, 4.44) | 7.00     |
| Lee et al., 2010                 | qPCR               | 1.88 (1.02, 3.45) | 0.00     |
| Zheng et al., 2010               | qPCR               | 8.70 (4.91, 1540.14) | 2.42     |
| Klahra et al., 2019              | ISH                | 20.95 (1.15, 383.02) | 2.37     |
| Klahra et al., 1993              | Serological assay  | 0.06 (0.00, 1.15) | 2.38     |
| Klahra et al., 1995              | Immunoenzymatic assay | 0.06 (0.00, 1.15) | 2.38     |
| Lee et al., 2013                 | Nested-PCR         | 2.86 (1.18, 6.90) | 50.38     |

### Figure 2. Odds ratio (OR) of laryngeal tissues associated with EBV (cases vs. controls), using a random-effects model, stratified by type of control (normal control and non-malignant lesions).

Note: Weights are from random effects analysis.
The hypothesis that viral infections are associated with the development of human cancers has been studied since the early 1960s, when the first human oncovirus was discovered in Burkitt’s lymphoma: the Epstein-Barr virus [36]. In 1973, Wolf, zur Hausen, and Becker [37] demonstrated by nucleic acid hybridization that epithelial cells of nasopharyngeal carcinomas harbor the EBV genome, which represented a breakthrough in this field by showing, for the first time, the involvement of EBV in epithelial malignancies.

One year later, the first study evaluating the involvement of EBV in laryngeal carcinoma was published; however, the authors failed to show any significant antibody titer differences between carcinoma and control groups, leading them to suggest that EBV is not etiologically related to LC [29]. Perhaps for this reason, there was a gap of nearly a decade until the next study investigating EBV in LC. Unlike the former, in the study by Břicháček et al. [10], the presence of EBNA (Epstein-Barr virus nuclear antigen) and EBV DNA was revealed in tumor cells of three patients with supraglottic laryngeal carcinoma (SGLC). Furthermore, the viral DNA was present in most if not all the tumor cells and, in two out of three EBV-infected tumors, foci of well-differentiated cells with keratinization were observed, indicating that EBV may be associated not only with undifferentiated carcinoma, a common feature of EBV-positive nasopharyngeal carcinomas. Although the authors suggest that at least some of these tumors are associated with EBV, they also recognize that these findings do not necessarily imply that EBV is etiologically involved in SGLC.

In the same year, Callaghan et al. [30] found the geometric mean titers (GMT) of IgG anti-VCA (viral capsid antigen) to be tenfold higher in patients with cancer of the larynx when compared to controls. According to the authors, the elevated IgG anti-VCA titers may indicate an activation of a latent EBV infection occurring after a state of immunosuppression which occurs in the host due to the effects of the tumor. Additionally, the GMTs for IgA anti-VCA in LC were significantly elevated compared to those of the control group. On the other hand, in the study by Lee et al. [28], serum IgA anti-VCA positivity was not associated with laryngeal EBV DNA positivity, but instead indicated previous repeated EBV infections or frequent reactivation of latent EBV in B lymphocytes. In 1989, a work identified a 200 kDa protein on the surface of primary cultures of a laryngeal carcinoma sharing an epitope with the C3d/EBV receptor molecule CD21 of B-cells [11].
Thereafter, other studies have sought to assess the relationship between EBV and laryngeal carcinoma, and the number of publications on this subject gradually increased in the following decades, but in a smaller proportion compared to other EBV-related tumors (such as nasopharyngeal and gastric carcinomas). As shown in Table 1, the prevalence of EBV in laryngeal carcinoma demonstrated variable results, ranging from 0 to 100%. It is worth noting that the two studies which presented prevalence of 100% applied serological assays. Moreover, the sample sizes, techniques employed, and targets also varied among the publications which, according to Goldenberg et al. [32], are partially responsible for the contradictory findings.

3.2. Controversial Aspects of the EBV–LC Relationship

Among the studies included, some were not able to detect EBV in their samples, either by ISH [2,16,19,20,22,26,31], immunohistochemistry (IHC) [16], or by PCR–Southern blot [34]. Furthermore, the studies by Lewensohn-Fuchs et al. [12] and Goldenberg et al. [32] detected EBV using nested-PCR and qPCR, respectively, but could not confirm viral presence by IHC and/or ISH.

It is worth mentioning that studies such as Yang et al. [22] and de Oliveira et al. [2] did not find ISH-positive cases even when evaluating expressive samples sizes: 93 and 110, respectively. These results are consistent with most studies involving EBV, in which oropharyngeal, hypopharyngeal and laryngeal carcinomas rarely show signals for this virus [22].

Regarding the studies employing PCR-based methods, most demonstrated positivity for EBV with an average prevalence around 50%. However, these results face the same dilemma observed in carcinomas from other anatomical sites, that is, the real meaning of the expressive PCR positivities given the impossibility of determining the precise source of viral DNA, whether from tumor or non-malignant cells (including lymphocytes and non-neoplastic epithelial cells). In this regard, when PCR-based methods are used for EBV detection, the results must be considered with caution because it has been estimated that EBV latently infected B-cells may be found in circulating cells in healthy individuals, and thus false-positive results must be considered [2,3]. In a study using qPCR, the authors assumed that the low levels of EBV detected by this highly sensitive molecular method may be related to the presence of the EBV genome in rare lymphoid or epithelial cells adjacent to the primary cancer [32].

In the present review, even without applying a time limitation filter in the searches, the number of articles retrieved evaluating the involvement of EBV in LC is still small. Moreover, many studies enrolled small samples, some applied indirect EBV detection methods (e.g., serological assays), while only a few were able to demonstrate the viral genome or its products (transcripts or proteins) in tumor cells, and there is a lack of information on the distribution patterns of staining. In addition, there are some relevant confounding variables, such as alcohol consumption and tobacco smoking that are traditional risk factors for HNSCC, as well as other oncogenic viruses that are also found in this site, sometimes in coinfections, which compromise the assessment of the role of EBV in the initiation and/or progression of laryngeal carcinomas. In this context, Mulder et al. [20] were unable to detect EBV in nine LC cases of non-smokers and non-drinkers.

Therefore, some authors recognize that the role of EBV in the pathogenesis of laryngeal carcinoma is still unclear [2–4,19,20,22,25,32,33]. In this context, Muderris et al. [4] assert that EBV is a very common virus which can be found in the mucosal cells of the upper aerodigestive tract in a considerable proportion of the population, and although EBV is present in cancer tissues of some of the LC cases, its presence has no effect on the pathogenesis of laryngeal carcinomas.

In a Turkish study, the identification of EBV DNA in 50% of patients with laryngeal carcinoma and in 41.2% of the vocal cord nodules indicates, according to the authors, that this agent does not seem to be directly associated with the pathogenesis of LC, but suggests a causal relationship involving EBV and proliferative diseases in the larynx [33].
study by Abdulamir et al. [24], serum levels of EBV IgG and IgA antibodies in CL patients were not significantly higher than those in the control group.

Three studies could not find any significant difference between EBV DNA positivity and smoking habits [4,32,33]. Two found no significant differences between EBV positivity and alcohol consumption and tumor grade [4,32], while two studies found no significant differences between EBV positivity and tumor stage [13,33]. Kiaris et al. [13] found no association between the presence of EBV with tumor differentiation and lymph nodes metastasis (N). A Greek study demonstrated that the EBV has no impact on tumor recurrence and the survival of the patients [15].

Interestingly, two studies failed to detect EBV by EBER-ISH in laryngeal lymphoepithelial carcinomas, denoting the peculiarity of this rare type of neoplasm [19,31]. Acuña et al. [19] estimated an annual incidence of 0.013/100,000 and prevalence in 0.2% of laryngeal and hypopharyngeal lymphoepithelial carcinomas. The origin of this kind of carcinoma of the larynx remains controversial. Only a third of the cases registered in the literature have shown the presence of EBV. It is a much smaller number when compared to the participation of this virus in nasopharyngeal carcinomas, where almost all cases are related to EBV [19]. Furthermore, the results of the aforementioned studies indicate that the percentage of involvement of EBV in these tumors appears to be even lower.

3.3. Evidence That Corroborates the Role of EBV in the Development of LC

Despite the controversy, some authors consider that EBV plays a role in the development of LC [5,6,13,21,23,25,27]. This meta-analysis revealed a relevant EBV pooled prevalence of 43.72% (Figure 1), and that EBV-infected individuals are 2.86 times more likely to develop laryngeal carcinoma when compared to the normal control (Figure 2). In the analysis with the control group composed of non-malignant lesions, the result of the odds ratio was 1.94 (95% CI: 1.18 to 3.21), while the overall analysis showed that EBV-infected individuals are at a 2.18 times greater risk of developing laryngeal carcinoma.

Although the possibility of false-negative cases is admitted in those studies investigating the presence of EBV in samples taken from FFPET, since formalin is a known inhibitor for PCR [4,27], in our analysis of subgroups, the employment of FFPET showed pooled prevalence at the same level as the other subgroups (serum and fresh frozen tissue) (Table 2). However, when separated into subgroups based on the type of technique, the PCR-based methods had the lowest pooled prevalence of 39.31% (Figure 1), and, indeed, more than half of the studies in this subgroup used FFPET. In addition, there were no expressive differences in the pooled prevalence by world regions.

Interestingly, the developed countries demonstrated higher pooled prevalence than developing ones. Although there is little information in this regard, one could argue that the difference observed between developing and developed countries might be related to the period of primary EBV infection. According to Ali et al. [27], due to some cultural practices, EBV exposure usually occurs in early childhood in developing countries, and primary infection in young children is typically associated with an unremarkable acute syndrome, while infection is often delayed in developed countries, and acute primary infection occurring in adolescence or adulthood can result in a self-limiting lymphoproliferative disorder known as infectious mononucleosis (IM). However, there is insufficient evidence to affirm that the delayed primo-infection may be related to the increased pooled prevalence verified in developed countries. Also, the difference in pooled prevalence may be due to the number of studies from developed and developing countries, 22 versus 6 (Table 2); nevertheless, the sample sizes were not that different: 692 versus 600.

In a recent case-control study, the EBV DNA positivity detected by qPCR was significantly higher in LC group (52% vs. 20%), showing that individuals with laryngeal EBV DNA positivity had a greater risk of developing LC (unadjusted OR = 4.3). Also, EBV DNA presence was positively correlated with BCL-2 expression (an anti-apoptotic protein) [28]. Although most EBER-ISH signals were localized into the nuclei of tumor-infiltrating lymphocytes, which according to the authors suggests the occurrence of the
hit-and-run mechanism of carcinogenesis at this epithelium, the high laryngeal EBER signal was identified as a poorer prognostic factor in LC.

Despite the debate on the high sensitivity of PCR-based methods which may incur false-positive results, in a multivariate analysis performed by Lee et al. [28], EBV DNA positivity was identified as one of the independent risk factors for LC (OR = 39.7; 95% CI: 3.3–478.0; p = 0.004).

Regarding histological approaches, although evidence on the location of EBV is scarce, some studies have shown distinct nuclear staining by ISH in tumor cells of laryngeal SCC [10,28,35]. It is worth mentioning that Bricháček et al. [10], unlike the others, employed ISH targeting the viral genome and were able to detect EBV in almost all tumor cells.

The cases in which EBV DNA was found but viral protein was not detected [12,32] may indicate that the virus is present but transcriptionally inactive [13]. In this scenario, other methods, such as the detection of EBV-RNA transcripts in tissues, can provide a broader understanding of transcriptional activity in latent and lytic EBV infection, which could bring new insights on its pathogenic role [3].

Some experiments have indicated that EBV infection may affect the immune response in the context of laryngeal carcinogenesis. For instance, the findings of Klatka et al. [6] point to an increased early activation of T-lymphocytes with reduction of the CD25+ population during recent or recurrent EBV infection and suggest that dysfunction of immune response in patients with LC might be associated with EBV infection [6]. In another study, the EBV infection seemed to have a definite effect in the secretion of immunosuppressive cytokines such as interleukin 10 (IL-10) and transforming growth factor β1 (TGFβ1). This suggests that cytokines may play a pathogenic role in EBV-associated LC, by both suppressing anti-tumor responses and by promoting tumor growth [5].

3.4. The Role of the Coinfections

The importance of studies focusing on the impact of coinfections on the malignant transformation of the laryngeal epithelium have also been highlighted, which may contribute to clarifying their association with the carcinogenic process and to guide prophylactic strategies [3,17,18]. In the opinion of Drop et al. [18], pathogenic infection may contribute but is not sufficient for the oncogenic process; therefore, a secondary coinfection with another virus may act as an important cofactor in triggering oncogenesis and/or tumor progression. The interaction of multiple oncoviruses may be an important risk factor in the neoplastic development that must be considered [3]. In a study utilizing nested-PCR, 15% (6/40) of the LC cases showed HPV/EBV coinfection [18]. In this sense, Liu et al. [23] suggest an association of laryngeal carcinogenesis and infection with the high-risk HPV-16, HPV-18, and EBV.

In our analysis, five studies reported EBV and HPV coinfections [3,12,15,17,18]. The present findings denote that laryngeal mucosa is another site that can harbor both agents simultaneously, likewise other HNSCC, as well as anogenital and breast carcinomas. Furthermore, it suggests that epithelium of the larynx might be susceptible to the same pattern of viral cooperation verified in the aforementioned carcinomas. The meaning of the coexistence of HPV and EBV in oral and anogenital carcinomas has already been addressed by our team in a previous review [8].

Although the role of EBV/HPV coinfection has been hypothesized, the coexistence of both viruses has not been proven to have an unfavorable implication in the prognosis of LC patients [15]. In addition, the results obtained by de Oliveira et al. [2] corroborate the hypothesis that HPV infection, but not EBV infection, has a role in the pathogenesis of a subset of laryngeal carcinomas. In fact, as shown in Table 1, some studies have evaluated the prevalence of coinfections between HPV and other viruses [3].

Other viruses detected in LC include HSV-1, CMV, HHV-8, HIV, BKV, and MCPV [3,10,17,18,35]. Additionally, Zheng et al. [25] detected a slightly higher viral load level of JCV in LC cases compared to laryngeal normal mucosa, but without statistical significance. Drop et al. [18] reported HPV + EBV + BKV coinfection in 4 out of 40 (10%) LC cases. However, there are in-
sufficient reports describing the epidemiology of viral coinfections in laryngeal carcinomas; hence, the role of these viruses in the pathogenesis of LCs is not yet fully elucidated [3,5].

In general, the limitations of the present study were related to the use of only two databases and the inclusion of articles exclusively published in English that may have restricted the number of records found. Moreover, as studies on EBV in laryngeal carcinoma are less common, a time period was not established in the searches, resulting in the selection of a greater number of articles using indirect methods for EBV detection, which along with the small sample sizes observed in some works and diversity of techniques employed are likely the main causes of the heterogeneity verified in our meta-analysis. Finally, the review being centered on observational studies, due the nature of the investigated subject, may have downgraded the strength of the current evidence.

4. Materials and Methods

4.1. Search Strategy

To investigate the association of EBV with laryngeal carcinoma, we conducted a systematic review with a meta-analysis of publications that were retrieved from the electronic scientific databases PubMed and Scopus, using the following search terms: “Epstein-Barr virus” and “laryngeal carcinoma”. In the PubMed database, the search was set to include all fields, while in Scopus the search was conducted based on the title, abstract, and keywords. In view of the limited number of articles available, no filter was applied for the time period; for this reason, the search covered a relatively long period (November 1973 to 3 September 2021).

The manuscripts were selected primarily through the analysis of titles and abstracts. The publications were reviewed independently by three authors and submitted to the following inclusion criteria: (i) articles written in English; (ii) articles addressing the association between carcinoma of the larynx and EBV; and (iii) original studies. Publications were excluded which (i) employed no EBV detection method (direct or indirect); (ii) were not classified as original research (i.e., letters to the editor, prefaces, comments, editorials, reviews, book chapters, and case reports); (iii) involved only squamous cell carcinomas from other locations in the upper aerodigestive tract and did not include any laryngeal cases, or combined the LC cases with tumors from other anatomical sites without presenting the values separately; (iv) were based on animal samples or models; or (v) were repeated documents. Any disagreement during the selection of records was resolved by the senior author.

Initially, we found 109 records in PubMed and 78 in Scopus. Fifty-nine duplicate records were excluded. After filtering for language and type of study and evaluating the connection of the content with the proposed aim, 31 articles were included in the systematic review (Figure 4). Full-text articles were obtained through the website of Coordination for the Improvement of Higher Education Personnel (CAPES), a restricted-access online library maintained by the Brazilian Ministry of Education. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) protocol. The protocol/review was not registered in any database. Ethics committee approval was not required.

4.2. Statistical Analysis

The statistical analysis was performed with the software Stata, version 12.0 (StataCorp; College Station, TX, USA), using the following commands: “metan”, “metafunnel”, and “metabias” [38]. First, EBV prevalence and confidence intervals (CI) were calculated for each study. The 95% CI was calculated using the Wilson method [39]. Then, we performed a meta-analysis to estimate the overall pooled prevalence of EBV. Analyses of subgroups were also performed after stratifying the potential sources of heterogeneity among the studies, including (i) viral detection technique (hybridization, immunological, or PCR-based methods), (ii) specimen collection method, (iii) geographic location of the study, and (iv) country’s development status. Articles lacking detailed information (total number of
cases and/or positive cases) for each type of specimen were excluded from the analysis due to the impossibility of calculating confidence intervals. The odds ratio (OR) and the corresponding 95% CI were estimated using the case-control studies. The heterogeneity among the results of the studies was evaluated with the I-squared ($I^2$) and the Q statistics, with the level of statistical significance set at 5% ($p < 0.05$). The EBV pooled prevalence was initially estimated with a fixed-effects model. However, due to the significant level of heterogeneity observed, we conducted a second analysis using the random-effects model of Der Simonian and Laird [40]. Studies reporting a prevalence of 0% or 100% were automatically excluded from the analysis. To assess publication bias, we used funnel plot and statistical tests (Egger’s test and Begg’s test).

To our knowledge, the present study represents the first systematic review with meta-analysis of the literature on the association of EBV with carcinoma of the larynx, with relevant evidence such as the expressive pooled EBV prevalence of 43.7% in samples from LC patients and the fact that EBV-infected individuals are 2.86 times more likely to develop laryngeal carcinoma. Despite the controversies, our findings indicate a possible role for EBV as a risk (co)factor in the development and/or progression of LC. Moreover, these tumors seem to share similarities with other HNSCCs, as well as with anogenital and breast carcinomas in which EBV can be found alone or in coinfection with high-risk genotypes of HPV, strengthening the thesis that both oncoviruses can cooperate in the epithelial transformation. There may also be an influence of EBV in the immunological response in the context of laryngeal carcinoma, providing an appropriate environment for the establishment of the LC, by promoting tumor growth and by suppressing anti-tumor responses. On the other hand, unlike other EBV-related carcinomas, there are still few studies in the literature dealing with this topic in the larynx; consequently, the location and distribution of EBV in the tissue remain controversial and there is a lack of information about its transcriptional activity, and, in turn, about the expression pattern of viral genes, whose available data only allow us to assume that EBERs are expressed in these tumors. Hence, further studies are needed in order to elucidate the inconsistencies. In this sense,
large and standardized case-control and cohort prospective studies, focusing on cases unrelated to confounding factors for the upper aerodigestive tract, combining different techniques and targets for EBV detection, may contribute to the understanding of the role played in this context. Also, in vitro studies are particularly important to investigate the effects of EBV on laryngeal carcinoma cell lines and possible underlying tumor mechanisms. Taken together, the present findings suggest that EBV may be associated with laryngeal carcinomas and contribute to expanding the knowledge on this oncovirus, in addition to encouraging new studies which, ultimately, may improve the clinical management and prevention of LC cases.

Author Contributions: Conceptualization, M.A.P.d.L.; methodology, M.A.P.d.L.; software, M.A.P.d.L.; validation, M.d.S.V.G., R.F.F.P.J. and S.d.E.L.P.; formal analysis, M.A.P.d.L. and C.G.L.d.S.; investigation, A.C.S.d.N.F., J.P.d.S.B., T.L.C., M.A.B.R. and A.D.L.L.; resources, M.A.P.d.L., M.d.S.V.G., R.F.F.P.J. and S.d.E.L.P.; data curation, M.A.P.d.L., A.C.S.d.N.F., J.P.d.S.B., T.L.C., M.A.B.R. and A.D.L.L.; writing—original draft preparation, M.A.P.d.L. and C.G.L.d.S.; visualization, M.d.S.V.G., R.F.F.P.J. and S.d.E.L.P.; supervision, M.A.P.d.L. and C.G.L.d.S.; project administration, M.A.P.d.L.; funding acquisition, M.A.P.d.L., M.d.S.V.G., R.F.F.P.J. and S.d.E.L.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: This study was funded by the Universidade Federal do Cariri (UFCA), through an internal postgraduate support program (Consolida-PG).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. De Oliveira, D.E.; Bacchi, M.M.; Macarenco, R.S.; Tagliarini, J.V.; Cordeiro, R.C.; Bacchi, C.E. Human papillomavirus and Epstein-Barr virus infection, p53 expression, and cellular proliferation in laryngeal carcinoma. Am. J. Clin. Pathol. 2006, 126, 284–293. [CrossRef]
3. Vazquez-Guillen, J.M.; Palacios-Saucedo, G.C.; Rivera-Morales, L.G.; Alonzo-Morado, M.V.; Burciaga-Bernal, S.B.; Montufar-Martinez, M.; Ortiz-Lopez, R.; Gonzalez-Villasana, V.; Martinez-Torres, A.C.; Serna-Hernandez, J.C.; et al. Infection and coinfection by human papillomavirus, Epstein-Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: A retrospective study. PeerJ 2018, 6, e5834. [CrossRef]
4. Muderris, T.; Rota, S.; Inal, E.; Fidan, I. Does Epstein-Barr virus infection have an influence on the development of laryngeal carcinoma? Detection of EBV by Real-Time Polymerase Chain Reaction in tumour tissues of patients with laryngeal carcinoma. Braz. J. Otorhinolaryngol. 2013, 79, 418–423. [CrossRef]
5. Rota, S.; Fidan, I.; Muderris, T.; Yesilyurt, E.; Lale, Z. Cytokine levels in patients with Epstein-Barr virus associated laryngeal carcinoma. J. Laryngol. Otol. 2010, 124, 990–994. [CrossRef]
6. Klatka, J.; Hymos, A.; Szkatura-Lupina, A.; Grywalska, E.; Klatka, B.; Terpiłowski, M.; Stepulak, A. T-Lymphocyte Activation Is Correlated with the Presence of Anti-EBV in Patients with Laryngeal Squamous Cell Carcinoma. In Vivo 2019, 33, 2007–2012. [CrossRef]
7. De Lima, M.A.P.; Teodoro, I.P.P.; Galiza, L.E.; Filho, P.H.B.M.; Marques, F.M.; Pinheiro Junior, R.F.F.; Macedo, G.E.C.; Facundo, H.T.; Da Silva, C.G.L.; Lima, M.V.A. Association between Epstein-Barr Virus and Oral Carcinoma: A Systematic Review with Meta-Analysis. Crit. Rev. Oncog. 2019, 24, 349–368. [CrossRef]
8. De Lima, M.A.P.; Teodoro, I.P.P.; Da Silva, C.G.L.; Lima, M.V.A. Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Oral and Anogenital Carcinogenesis: Potential Tumorigenic Pathways. Crit. Rev. Oncog. 2019, 24, 403–413. [CrossRef]
9. Shi, Y.; Peng, S.L.; Yang, L.F.; Chen, X.; Yao, Y.J.; Cao, Y. Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. Chin. J. Cancer 2016, 35, 16. [CrossRef]
10. Brichácek, B.; Hirsch, I.; Sibl, O.; Vilikusová, E.; Vonka, V. Association of some supraglottic laryngeal carcinomas with EB virus. Int. J. Cancer 1983, 32, 193–197. [CrossRef]
11. Young, L.S.; Dawson, C.W.; Brown, K.W.; Rickinson, A.B. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. *Int. J. Cancer* 1989, 43, 786–794. [CrossRef]

12. Lewersohn-Fuchs, I.; Munck-Wikland, E.; Berke, Z.; Magrussen, K.P.; Pallesen, G.; Auer, G.; Lindholm, J.; Linde, A.; Aberg, B.; Rubio, C.; et al. Involvement of aberrant p53 expression and human papillomavirus in carcinoma of the head, neck and esophagus. *Anticancer Res.* 1994, 14, 1281–1285.

13. Kiaris, H.; Ergazaki, M.; Segas, J.; Spandios, D.A. Detection of Epstein-Barr virus genome in squamous cell carcinomas of the larynx. *Int. J. Biol. Markers* 1995, 10, 211–215. [CrossRef]

14. Zbären, P.; Borisch, B.; Läng, H.; Greiner, R. Undifferentiated carcinoma of nasopharyngeal type of the laryngopharyngeal region. *Otolaryngol. Head Neck Surg.* 1997, 117, 688–693. [CrossRef]

15. Vlachitis, K.; Nikolaou, A.; Markou, K.; Fountzilas, G.; Daniilidis, I. Clinical and molecular prognostic factors in operable laryngeal cancer. *Eur. Arch. Otorhinolaryngol.* 2005, 262, 890–898. [CrossRef]

16. Moyano, S.; Ordi, J.; Caballero, M.; Garcia, F.; Diaz, A.; De Sanjose, S.; Cardesa, A.; Alos, L. Laryngeal squamous cell carcinoma in HIV-positive patients: Lack of association with human papillomavirus infection. *HIV Med.* 2009, 10, 634–639. [CrossRef]

17. Polz-Gruszka, D.; Stec, A.; Dworzaniski, J.; Polz-Dacewicz, M. Detection of Epstein-Barr virus DNA by polymerase chain reaction in head and neck Cancer of Non-Smokers and Non-Drinkers. *Front. Oncol.* 2020, 10, 560434. [CrossRef] [PubMed]

18. Jeng, K.C.; Hsu, C.Y.; Liu, M.T.; Chung, T.T.; Liu, S.T. Prevalence of Taiwan variant of Epstein-Barr virus in throat washings from patients with head and neck tumors in Taiwan. *J. Clin. Microbiol.* 1994, 32, 28–31. [CrossRef]

19. Acuña, G.; Gómez, M.; Temprana-Salvador, J.; García-Bragado, F.; Alós, L.; Ordi, J.; Cardesa, A.; Nadal, A. Human papillomavirus in laryngeal and hypopharyngeal lymphoepithelial carcinoma. *Mod. Pathol.* 2019, 32, 621–626. [CrossRef]

20. Mulder, F.J.; Klufah, F.; Janssen, F.M.E.; Farshadpour, F.; Willems, S.M.; De Bree, R.; Gut, J.; Zur Hausen, A.; Van den Hout, M.; Kremer, B.; Speel, E. Presence of Human Papillomavirus and Epstein-Barr Virus, but Absence of Merkel Cell Polyomavirus, in Head and Neck Cancer of Non-Smokers and Non-Drinkers. *Front. Oncol.* 2020, 10, 560434. [CrossRef] [PubMed]

21. Lewensohn-Fuchs, I.; Munck-Wikland, E.; Berke, Z.; Magnusson, K.P.; Pallesen, G.; Auer, G.; Lindholm, J.; Linde, A.; Aberg, B.; Abbas, K.A. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. *BMC Public Health* 2008, 8, 400. [CrossRef]

22. Zheng, Y.; Xia, P.; Zheng, H.C.; Takahashi, H.; Masuda, S.; Takano, Y. The screening of viral risk factors in tongue and larynx. *Int. J. Cancer* 1995, 43, 786–794. [CrossRef]

23. Lee, L.A.; Fang, T.J.; Li, H.Y.; Chuang, H.H.; Kang, C.J.; Chang, K.P.; Liao, C.T.; Chen, T.C.; Huang, C.G.; Yen, T.C. Effects of Epstein-Barr Virus Infection on the Risk and Prognosis of Primary Laryngeal Squamous Cell Carcinoma: A Hospital-Based Case-Control Study in Taiwan. *Cancers* 2021, 13, 1741. [CrossRef] [PubMed]

24. Abdulamir, A.S.; Hafidh, R.R.; Abdulmuaimen, N.; Abubakar, F.; Abbas, K.A. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. *BMC Public Health* 2008, 8, 400. [CrossRef]

25. Choe, J.Y.; Yun, J.Y.; Nam, S.J.; Kim, J.E. Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma. *Korean J. Pathol.* 2012, 46, 515–522. [CrossRef] [PubMed]

26. Ali, S.H.M.; Alsabti, A.A.; Al-Lebawi, N.S.; Al-Awany, S.H.M.; Al-Ghurair, A.A.A. Molecular Tracing of Abundances of Latent Epstein-Barr Virus Early Repeats in Laryngeal Carcinomatous Tissues from a Group of Iraqi Patients: A Possibility of an Early Event in Laryngeal Carcinogenesis. *Biochem. Cell. Arch.* 2018, 18, 421–427.

27. Lee, L.A.; Fang, T.J.; Li, H.Y.; Chuang, H.H.; Kang, C.J.; Chang, K.P.; Liao, C.T.; Chen, T.C.; Huang, C.G.; Yen, T.C. Effects of Epstein-Barr Virus Infection on the Risk and Prognosis of Primary Laryngeal Squamous Cell Carcinoma: A Hospital-Based Case-Control Study in Taiwan. *Cancers* 2021, 13, 1741. [CrossRef] [PubMed]

28. Choe, J.Y.; Yun, J.Y.; Nam, S.J.; Kim, J.E. Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma. *Korean J. Pathol.* 2012, 46, 515–522. [CrossRef] [PubMed]

29. Choe, J.Y.; Yun, J.Y.; Nam, S.J.; Kim, J.E. Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma. *Korean J. Pathol.* 2012, 46, 515–522. [CrossRef] [PubMed]

30. Abdulamir, A.S.; Hafidh, R.R.; Abdulmuaimen, N.; Abubakar, F.; Abbas, K.A. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. *BMC Public Health* 2008, 8, 400. [CrossRef]

31. MacMillan, C.; Kapadia, S.B.; Finkelstein, S.D.; Nalesnik, M.A.; Barnes, L. Lymphoepithelial carcinoma of the larynx and hypopharynx: Study of eight cases with relationship to Epstein-Barr virus and p53 gene alterations, and review of the literature. *Hum. Pathol.* 1996, 27, 1172–1179. [CrossRef]

32. Goldenberg, D.; Benoit, N.E.; Begum, S.; Westra, W.H.; Cohen, Y.; Koch, W.M.; Sidransky, D.; Califano, J.A. Epstein-Barr virus in head and neck cancer assessed by quantitative polymerase chain reaction. *Laryngoscope* 2004, 114, 1027–1031. [CrossRef] [PubMed]

33. Gök, U.; Ozdarendel, A.; Keleş, E.; Bulut, Y.; Cobanoğlu, B. Detection of Epstein-Barr virus DNA by polymerase chain reaction in surgical specimens of patients with squamous cell carcinoma of the larynx and vocal cord nodules. *Kulak Burun Bogaz Ihtisas Dergisi* 2003, 11, 134–138.

34. Chow, C.W.; Tabrizi, S.N.; Tiedemann, K.; Waters, K.D. Squamous cell carcinomas in children and young adults: A new wave of a very rare tumor? *J. Pediatr. Surg.* 2007, 42, 2035–2039. [CrossRef] [PubMed]
35. McLemore, M.S.; Haigentz, M.; Smith, R.V.; Nuovo, G.J.; Alos, L.; Cardesa, A.; Brandwein-Gensler, M. Head and neck squamous cell carcinomas in HIV-positive patients: A preliminary investigation of viral associations. *Head Neck Pathol.* 2010, 4, 97–105. [CrossRef]

36. Epstein, M.A.; Achong, B.G.; Barr, Y.M. Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma. *Lancet* 1964, 1, 702–703. [CrossRef]

37. Wolf, H.; Zur Hausen, H.; Becker, V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. *Nat. New Biol.* 1973, 244, 245–247. [CrossRef] [PubMed]

38. Harris, R.J.; Deeks, J.J.; Altman, D.G.; Bradburn, M.J.; Harbord, R.M.; Sterne, J.A.C. Metan: Fixed- and Random-Effects Meta-Analysis. *Stata J.* 2008, 8, 3–28. [CrossRef]

39. Newcombe, R.G. Two-sided confidence intervals for the single proportion: Comparison of seven methods. *Stat. Med.* 1998, 17, 857–872. [CrossRef]

40. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. *Control Clin. Trials* 1986, 7, 177–188. [CrossRef]